M. K. Smith

HIV-1 reverse transcriptase variants: molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method.

W. L. Jorgensen, S. Hughes, E. Arnold, 2003, Drug design and discovery.

Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.

S. Hughes, E. Arnold, K. Das, 2007, Journal of medicinal chemistry.

Assault on resistance: the use of computational chemistry in the development of anti-HIV drugs.

W. L. Jorgensen, M. K. Smith, Richard H. Smith, 2006, Current pharmaceutical design.

Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.

A. D. Clark, Jianping Ding, R. Pauwels, 1996, Journal of molecular biology.